MedTrace Logo

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

NCT02252406 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-04-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effects of ranolazine on different markers of cardiometabolic disease in women with stable angina.

Conditions

  • Stable Angina
  • Metabolic Syndrome

Interventions

DRUG

Ranolazine

Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24

OTHER

Placebo

Matching placebo tablets daily for 24 weeks.

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Gladys P Velarde, MD, FACC · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2018-12-17
Completion
2019-05-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02252406 on ClinicalTrials.gov